Dec 26, 2023 03:59AM
Dec 26, 2023 02:00AM
Dec 6, 2023 04:10PM
Dec 6, 2023 04:05PM
Dec 1, 2023 04:06PM
Dec 1, 2023 04:05PM
Nov 13, 2023 04:05PM LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Oct 25, 2023 04:05PM
Oct 24, 2023 06:59AM
Oct 24, 2023 06:59AM
Aug 28, 2023 04:05PM
Aug 28, 2023 04:05PM
Aug 14, 2023 04:05PM
Aug 3, 2023 04:05PM LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
Aug 2, 2023 10:00AM
Jul 18, 2023 08:00AM
Jul 12, 2023 08:00AM
Jun 26, 2023 08:00AM
Jun 6, 2023 04:05PM
Jun 6, 2023 04:05PM
May 11, 2023 04:15PM LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:03AM
May 11, 2023 07:00AM
Apr 26, 2023 08:00AM
Apr 26, 2023 08:00AM
Apr 21, 2023 08:15AM
Apr 21, 2023 08:01AM
Apr 21, 2023 08:00AM LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertroph
Mar 27, 2023 08:36AM
Feb 28, 2023 05:00PM
Dec 19, 2022 07:06AM
Dec 19, 2022 07:00AM
Dec 13, 2022 05:00PM
Dec 13, 2022 05:00PM
Nov 10, 2022 04:05PM LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 9, 2022 04:05PM
Nov 3, 2022 07:30AM
Nov 1, 2022 04:05PM
Aug 11, 2022 04:05PM
Aug 10, 2022 08:00AM
May 12, 2022 08:00AM
May 12, 2022 07:30AM BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
May 9, 2022 08:00AM
May 3, 2022 08:00AM
May 3, 2022 08:00AM
Apr 29, 2022 08:16AM
Apr 29, 2022 08:15AM
Apr 7, 2022 07:08PM
Mar 30, 2022 04:39PM LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Feb 24, 2022 07:30AM

1,157,615 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All